Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Apolipoprotein M in patients with chronic kidney disease

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Plasma Cotinine Cutoff for Distinguishing Smokers From Nonsmokers Among Persons Living With HIV

    Research output: Contribution to journalJournal articleResearch

  4. Galnt11 regulates kidney function by glycosylating the endocytosis receptor megalin to modulate ligand binding

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Apolipoprotein M-bound sphingosine-1-phosphate regulates blood-brain barrier paracellular permeability and transcytosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND AIMS: Plasma apolipoprotein M (APOM) is bound to HDL-particles and has anti-atherogenic effects. The present study explored whether plasma APOM is reduced in patients with chronic kidney disease (CKD), and associated with cardiovascular disease (CVD). In addition, we tested the hypothesis that the excretion of APOM into the urine is increased in patients with kidney disease.

METHODS: Plasma samples were collected from a cohort of patients with CKD stages 1 to 5D (N = 409) and controls (N = 35). Urine was collected from 47 subjects. Plasma APOM was measured with sandwich ELISA and urine APOM with competitive ELISA.

RESULTS: Plasma APOM levels were reduced in patients with CKD stages 3-5D as compared to patients with CKD stages 1 + 2 and controls (p < 0.01). CKD patients with known CVD displayed even further reduction in plasma APOM levels than CKD patients without known CVD (p < 0.001). Fast-phase liquid chromatography showed that plasma APOM was primarily associated with HDL-cholesterol (HDL-C) across CKD stages. Accordingly, when plasma APOM values were corrected for HDL-C, a significant difference only persisted between patients with CKD stage 3 and stages 1 + 2 (p < 0.05), and the difference between CKD patients with and without known CVD disappeared. Urine APOM/creatinine ratio was not significantly increased in patients with kidney disease.

CONCLUSIONS: The results show that the difference in plasma APOM levels observed between patients with mild and advanced CKD may mainly be due to differences in plasma HDL-C. Whether APOM plays a role in human uremic atherogenesis warrants further experimental studies.

Original languageEnglish
JournalAtherosclerosis
Volume275
Pages (from-to)304-311
Number of pages8
ISSN0021-9150
DOIs
Publication statusPublished - Aug 2018

ID: 55401871